Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


Contact: Karen Honey
Journal of Clinical Investigation

Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:

(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
Breaking Biology Technology:
Cached News: